Approximately 72% of GLP-1 receptor agonist prescriptions are dominated by liraglutide and semaglutide combined
7RA3: Sun B, Willard FS, Feng D, Alsina-Fernandez J, Chen Q, Vieth M, Ho JD, Showalter AD, Stutsman C, Ding L, Suter TM, Dunbar JD, Carpenter JW, Mohammed FA, Aihara E, Brown RA, Bueno AB, Emmerson PJ, Moyers JS, Kobilka TS, Coghlan MP, Kobilka BK, Sloop KW
doi: 10.3389/fmed.2023.1124275 Received 14 December 2022 Accepted 27 February 2023 Published 22 March 2023 Volume 10 - 2023 Edited by Ana Sandoval-Rodriguez, University of Guadalajara, Mexico Reviewed by Angelo Armandi, University of Turin, Italy
The decision to switch medications should always be made with a prescriber based on the full clinical picture, not on genetics alone
Skibickas lab has found that women, on average, lose more weight than men on equivalent doses, possibly due to interactions between GLP-1 signaling and estrogen